Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19

被引:153
作者
Zhou, Mei [1 ]
Wang, Xueyan [1 ]
Van Phung [1 ]
Lindhout, Darrin A. [1 ]
Mondal, Kalyani [1 ]
Hsu, Jer-Yuan [1 ]
Yang, Hong [1 ]
Humphrey, Mark [1 ]
Ding, Xunshan [1 ]
Arora, Taruna [1 ]
Learned, R. Marc [1 ]
DePaoli, Alex M. [1 ]
Tian, Hui [1 ]
Ling, Lei [1 ]
机构
[1] NGM Biopharmaceut Inc, San Francisco, CA 94080 USA
关键词
FIBROBLAST-GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; LEPTIN RECEPTOR; GENE-EXPRESSION; TRANSGENIC MICE; TUMOR-GROWTH; KAPPA-B; LIVER; STAT3; CANCER;
D O I
10.1158/0008-5472.CAN-14-0208
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Hepatocellular carcinoma (HCC), one of the leading causes of cancer-related death, develops from premalignant lesions in chronically damaged livers. Although it is well established that FGF19 acts through the receptor complex FGFR4-beta-Klotho (KLB) to regulate bile acid metabolism, FGF19 is also implicated in the development of HCC. In humans, FGF19 is amplified in HCC and its expression is induced in the liver under cholestatic and cirrhotic conditions. In mice, ectopic overexpression of FGF19 drives HCC development in a process that requires FGFR4. In this study, we describe an engineered FGF19 (M70) that fully retains bile acid regulatory activity but does not promote HCC formation, demonstrating that regulating bile acid metabolism is distinct and separable from tumor-promoting activity. Mechanistically, we show that FGF19 stimulates tumor progression by activating the STAT3 pathway, an activity eliminated by M70. Furthermore, M70 inhibits FGF19-dependent tumor growth in a rodent model. Our results suggest that selectively targeting the FGF19-FGFR4 pathway may offer a tractable approach to improve the treatment of chronic liver disease and cancer. (C) 2014 AACR.
引用
收藏
页码:3306 / 3316
页数:11
相关论文
共 45 条
[1]
Beenken A, 2012, ADV EXP MED BIOL, V728, P1, DOI 10.1007/978-1-4614-0887-1_1
[2]
The FGF family: biology, pathophysiology and therapy [J].
Beenken, Andrew ;
Mohammadi, Moosa .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (03) :235-253
[3]
Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[4]
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC [J].
Calvisi, DF ;
Ladu, S ;
Gorden, A ;
Farina, M ;
Conner, EA ;
Lee, JS ;
Factor, VM ;
Thorgeirsson, SS .
GASTROENTEROLOGY, 2006, 130 (04) :1117-1128
[5]
Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3 [J].
Chen, Kuen-Feng ;
Tai, Wei-Tien ;
Liu, Tsung-Hao ;
Huang, Hsiang-Po ;
Lin, Yu-Chin ;
Shiau, Chung-Wai ;
Li, Pui-Kai ;
Chen, Pei-Jer ;
Cheng, Ann-Lii .
CLINICAL CANCER RESEARCH, 2010, 16 (21) :5189-5199
[6]
Emerging Role of Fibroblast Growth Factors 15/19 and 21 as Metabolic Integrators in the Liver [J].
Cicione, Claudia ;
Degirolamo, Chiara ;
Moschetta, Antonio .
HEPATOLOGY, 2012, 56 (06) :2404-2411
[7]
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models [J].
Desnoyers, Lr ;
Pai, R. ;
Ferrando, Re ;
Hotzel, K. ;
Le, T. ;
Ross, J. ;
Carano, R. ;
D'Souza, A. ;
Qing, J. ;
Mohtashemi, I. ;
Ashkenazi, A. ;
French, Dm .
ONCOGENE, 2008, 27 (01) :85-97
[8]
CURRENT CONCEPTS Hepatocellular Carcinoma [J].
El-Serag, Hashem B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (12) :1118-1127
[9]
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models [J].
French, Dorothy M. ;
Lin, Benjamin C. ;
Wang, Manping ;
Adams, Camellia ;
Shek, Theresa ;
Hoetzel, Kathy ;
Bolon, Brad ;
Ferrando, Ronald ;
Blackmore, Craig ;
Schroeder, Kurt ;
Rodriguez, Luis A. ;
Hristopoulos, Maria ;
Venook, Rayna ;
Ashkenazi, Avi ;
Desnoyers, Luc R. .
PLOS ONE, 2012, 7 (05) :e36713
[10]
Fibroblast growth factor 19 increases metabolic rate I and reverses dietary and leptlin-deficient diabetes [J].
Fu, L ;
John, LM ;
Adams, SH ;
Yu, XX ;
Tomlinson, E ;
Renz, M ;
Williams, PM ;
Soriano, R ;
Corpuz, R ;
Moffat, B ;
Vandlen, R ;
Simmons, L ;
Foster, J ;
Stephan, JP ;
Tsai, SP ;
Stewart, TA .
ENDOCRINOLOGY, 2004, 145 (06) :2594-2603